Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability

7 Dec 2021

Abstract excerpt

BACKGROUND: Microsatellite instability-high (MSI-H)/mismatch repair deficiency (dMMR) is a biomarker for responses to immune checkpoint inhibitors (ICIs). Whether mechanisms underlying microsatellite instability alter responses to ICIs is unclear. This article reports data from a prospective phase 2 pilot study of pembrolizumab in patients with recurrent MSI-H endometrial cancer (EC) analyzed by whole exome...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Endometrial and Cervical Cancer Treatments
Share to Genetic factors in colorectal cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34875107
DOI: 10.1002/cncr.34025

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instabilityPMID 34875107Read ↗

Traditional and New Views on MSI-H/dMMR Endometrial Cancer.Semantic proximity Read ↗

Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune MicroenvironmentSemantic proximity Read ↗

A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)Semantic proximity Read ↗

The advent of immune checkpoint inhibition for the treatment of patients with primary advanced or recurrent dMMR/MSI high endometrial cancer in 2025.Semantic proximity Read ↗

A tale of two pathways: Review of immune checkpoint inhibitors in DNA mismatch repair‐deficient and microsatellite instability‐high endometrial cancersSemantic proximity Read ↗

Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing DataSemantic proximity Read ↗

Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial CancerSemantic proximity Read ↗

Real-world prevalence of microsatellite instability testing and related status in women with advanced endometrial cancer in EuropeSemantic proximity Read ↗

Characterization of mismatch‐repair/microsatellite instability‐discordant endometrial cancersSemantic proximity Read ↗

Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-CancerSemantic proximity Read ↗

Gynecological Cancers Caused by Deficient Mismatch Repair and Microsatellite InstabilitySemantic proximity Read ↗

Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.